Evidence map›Paper›PMID 40444052›Full record

ArticleFrontiers in pharmacology2025

Successful treatment of an elderly patient with relapsed/refractory angioimmunoblastic T-cell lymphoma with the PI3Kδ inhibitor linperlisib: a Case Report.

Ming-Qiang Chu, Ting-Juan Zhang, Qian Yang, Yuan Feng, Chao Lu, Yong-Hui Ji, Jun Qian, Jing-Dong Zhou

Abstract readCase Reports
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ming-Qiang Chu *Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Ting-Juan Zhang *Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Qian Yang *Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Yuan FengDepartment of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Chao LuDepartment of Medical Imaging, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Yong-Hui JiDepartment of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Jun QianDepartment of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Jing-Dong ZhouDepartment of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angioimmunoblastic T-cell lymphoma (AITL), a highly aggressive peripheral T-cell lymphoma (PTCL), carries a poor prognosis in elderly patients due to frequent relapse and limited salvage options after multiline therapy. We present the case of an 80-year-old woman with relapsed/refractory (R/R) AITL who relapsed after CHOP and exhibited resistance to the following sequential therapies: second-line chidamide plus COP and third-line chidamide with mitoxantrone hydrochloride liposome. Molecular analysis revealed

Indexed as

angioimmunoblastic T-cell lymphomacase reportelderly patientslinperlisibPI3Kδ inhibitorrelapsed/refractorysalvage therapy

Identifiers

PMID40444052
PMCPMC12119530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.